Magnitude and time course of platelet inhibition with Aggrenox and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial

European Journal of Pharmacology
Victor L SerebruanyCharles H Hennekens

Abstract

The European Stroke Prevention Study showed greater stroke prevention for Aggrenox than either for aspirin or dipyridamole alone. To test whether Aggrenox has superior antiplatelet properties to aspirin alone we conducted the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial. Forty patients with prior ischemic stroke not taking aspirin for at least 30 days were randomized to Aggrenox (2 pills/daily) or aspirin (81 mg plus matching placebo/daily) for 30 days. Platelet function was assessed at baseline, 24 h, and days 3, 7, 15, and 30 by aggregometry, flow cytometry and cartridge-based analyzers. Both Aggrenox and aspirin provided fast and sustained platelet inhibition. Aggrenox(R), however, especially after 15 days, showed significant prolongation of the closure time (P=0.04), diminished expression of platelet/endothelial cell adhesion molecule-1 (PECAM-1) (P=0.01), glycoprotein IIb (GPIIb) antigen (P=0.02), and GPIIb/IIIa activity (P=0.01) by PAC-1 C antibody, CD63 (P=0.03), as well as inhibition of Protease Activated Receptors (PAR-1) associated with intact (SPAN12, P=0.01) and cleaved (WEDE15, P=0.01) thrombin receptors as compared with aspirin. Surprisingly, GPIb expression increased, especially after aspirin. In the ...Continue Reading

References

Jun 18, 1991·European Journal of Pharmacology·H BultA G Herman
May 1, 1985·Proceedings of the National Academy of Sciences of the United States of America·V M DixitW A Frazier
May 14, 1987·The New England Journal of Medicine·G A FitzGerald
Jan 1, 1981·European Journal of Clinical Pharmacology·G G Neri SerneriA Morettini
Feb 1, 1995·Free Radical Biology & Medicine·L IulianoF Violi
Nov 1, 1994·Atherosclerosis·M L SelleyN G Ardlie
Feb 1, 1994·The Journal of Clinical Investigation·G H van ZantenJ J Sixma
Mar 20, 1993·Annals of the New York Academy of Sciences·K A Ault
May 13, 1998·British Journal of Clinical Pharmacology·C R Gibbs, G Y Lip
May 14, 1998·Seminars in Thrombosis and Hemostasis·E F MammenD J Nugent
Mar 17, 1999·The Journal of Clinical Investigation·M L KahnS R Coughlin
Jun 14, 2000·European Journal of Pharmacology·J P De La CruzF Sánchez de la Cuesta
Sep 9, 2000·Current Opinion in Cell Biology·J Lawler
Jan 12, 2001·Journal of the American College of Cardiology·O O AkinboboyeS R Bergmann
May 25, 2002·The Journal of Laboratory and Clinical Medicine·Kenneth A SchwartzJohn M Davis
Aug 13, 2002·Arteriosclerosis, Thrombosis, and Vascular Biology·Takuya IchiiYoshiki Nishizawa
Apr 16, 2003·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·Marcus E McKenzieVictor L Serebruany
May 14, 2004·Thrombosis Research·Victor L SerebruanyCharles H Hennekens

❮ Previous
Next ❯

Citations

Apr 26, 2006·Current Treatment Options in Cardiovascular Medicine·Christopher D Booze, Victor L Serebruany
Sep 22, 2012·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·W O TobinD J H McCabe
Dec 10, 2009·Vascular Health and Risk Management·Rakesh K SharmaGirish Bhatt
Dec 29, 2013·International Journal of Pharmaceutics·Admassu AbebeAlberto M Cuitiño
Jan 15, 2013·Translational Research : the Journal of Laboratory and Clinical Medicine·Roza Badr EslamSimon Panzer
Oct 27, 2012·The Annals of Thoracic Surgery·Victor A FerrarisUNKNOWN Society of Thoracic Surgeons
Mar 10, 2009·Fundamental & Clinical Pharmacology·Victor L SerebruanyJames J Ferguson
Aug 22, 2006·Pharmacology & Therapeutics·Marie LordkipanidzéJean G Diodati
Nov 18, 2005·American Heart Journal·Victor L SerebruanyJames J Ferguson
Feb 22, 2012·Pharmaceutical Development and Technology·Divyakant DesaiPeter Timmins
Apr 25, 2007·Circulation·Andrew O Maree, Desmond J Fitzgerald
Aug 1, 2007·Expert Review of Pharmacoeconomics & Outcomes Research·Darya MalininaVictor Serebruany
Jul 28, 2005·The Journal of Pharmacology and Experimental Therapeutics·Subrata ChakrabartiJane E Freedman
Sep 3, 2011·Cardiovascular Therapeutics·Jesse DawsonMatthew R Walters

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Stroke

A stroke occurs when blood supply to the brain is interrupted depriving the brain of oxygen and nutrients. This feed focuses cerebrovascular accidents including ischemic and paralytic stroke.

Antibodies: Agglutination

Antibody-mediated agglutination is the clumping of cells in the presence of antibody, which binds multiple cells together. This enhances the clearance of pathogens. Find the latest research on antibody-mediated agglutination here.

Brain Ischemia

Brain ischemia is a condition in which there is insufficient blood flow to the brain to meet metabolic demand. Discover the latest research on brain ischemia here.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Related Papers

Translational Research : the Journal of Laboratory and Clinical Medicine
Roza Badr EslamSimon Panzer
The Annals of Thoracic Surgery
Victor A FerrarisH Reich
Lancet
Graeme J Hankey, John W Eikelboom
© 2021 Meta ULC. All rights reserved